Stockreport

TScan Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]

TScan Therapeutics, Inc.  (TCRX) 
PDF Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 10%. Looking ahead, revenue is forecast to grow 66% p.a. on average du [Read more]